Navigation Links
Comprehensive Safety Tests Published on Ruyan(R) Smoking Alternatives

Tests Conducted in New Zealand and Canada Find Ruyan E-cigarettes Safe;

Results Apply Only to Ruyan Products

MINNEAPOLIS, Oct. 28 /PRNewswire/ -- Ruyan America, Inc., announced today the publication of a report that tested the safety of its electronic smoking alternatives, specifically the nicotine cartridges that produce the smoke-like vapor that users find satisfies their desire for tobacco. The report summary states that the test results confirm that the Ruyan(R) E-cigarette is a safe alternative to smoking, very safe relative to cigarettes and safe in absolute terms on all measurements that were applied. The summary also notes that the report findings refer only and specifically to Ruyan products.

The tests were conducted by Dr. Murray Laugesen of Health New Zealand, Ltd, who also authored the report, and they were performed by seven leading government, university and commercial laboratories in New Zealand and Canada. Ruyan funded the tests and the report, but had no role in the design of the tests or any input with respect to the findings in the report. No completed tests were withheld from the report, which can be viewed in its entirety at

Alexander Chong, CEO of Ruyan America, Inc., commented, "We are pleased to have Dr. Laugesen publish these results, validating the safety of our groundbreaking products and this relatively new product category. But, as the summary states, these results apply only to Ruyan and its products."

Chong went on to note how important these tests are expected to be to distributors, retailers and consumers of the products. "Given how critical ingredients like flavorings and scents are to the overall safety profile of the product, we believe that it's very important for distributors, retailers and consumers to demand this kind of information from anyone claiming the right to market or sell similar products."

About the Products

The Ruyan V-8 E-cigarette is a sophisticated electronic device with patents granted in China and Europe and Patents Pending in the US. The device atomizes purified, liquid nicotine and produces a vapor that, when inhaled, satisfies a smoker's craving for tobacco. The vapor contains none of the harmful chemicals commonly found in traditional cigarette smoke and none of those chemicals considered poisonous or carcinogenic. When and if the vapor is expelled, it does not contain any of the harmful chemicals found in second hand smoke. Cartridges for the Ruyan E-cigarette are available in regular and menthol flavors. The Ruyan V-8 was named the most innovative new product at the 2008 Tobacco Plus Expo.

The Ruyan Vegas E-cigar comes in two varieties, the Classic, which contains 16 mg of nicotine, and the Freestyle, which is nicotine free. Both E-cigars produce a thick, flavorful vapor that satisfies a user's tobacco cravings. The Ruyan Vegas E-cigar was named the most marketable new product at the 2008 Tobacco Plus Expo.

Ruyan smoking alternatives do not produce tobacco smoke or smoke of any kind and, as such, do not violate smoking bans or restrictions. Users have successfully satisfied tobacco urges in all states and in all places where smoking is otherwise restricted.

About the Company

Ruyan America, Inc. is a U.S.-based joint venture partner of Ruyan Holdings, Ltd. of Hong Kong. Mr. Hon Lik, the inventor and patent holder of the E-cigarette and the atomizing technology that is critical to it, the E- cigar and the E-pipe, is the Vice-Chairman of Ruyan Holdings, Ltd. and the Chairman of Ruyan America. These products, varieties of replacement cartridges and their accessories are designed, manufactured and sold for the cigarette alternative/smoking substitution market. They allow smokers to satisfy their tobacco cravings in places and situations where they otherwise cannot smoke by law, regulation or common courtesy. Ruyan is the only manufacturer of E-cigarette pursuant to Mr. Hon's patents and Ruyan America is the only Company providing E-cigarettes, E-cigars, E-pipes, their cartridges and accessories to distributors and retailers in concert with safety test results, product liability insurance, detailed ingredient lists, documentation of proprietary intellectual property and the support of a $4 million Direct Response Television campaign. Information about the company and its products can be found at and the company's DRTV infomercial can be viewed at

Warning: Be advised that nicotine is addictive. The Ruyan products have not been evaluated by the US FDA. They are not intended to be drug products that diagnose, treat, cure or mitigate any disease or condition. Do not use these products if you are under the age of 21; if you are a non-smoker, if you have a demonstrated sensitivity to nicotine or any combination of common inhalants; or if you are pregnant or nursing.

For Additional Information, Please Contact:

William P. Bartkowski, President

Ruyan America, Inc.


SOURCE Ruyan America, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Siemens Showcases Its Most Comprehensive and Advanced Breast Care Portfolio
2. Clinsys(R) TPS Teams Provide Comprehensive Clinical Development Plans
3. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
4. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
5. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
6. Five-Year Data From Taxus II Clinical Trial Highlights Safety and Efficacy of Taxus(R) Stent Compared to Bare-Metal Stent
7. Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent
8. Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine
9. R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
10. Ortho Biotech Reiterates Confidence in PROCRIT(R) (Epoetin alfa) Safety and Efficacy When Used According to Label
11. New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy
Post Your Comments:
(Date:11/30/2015)... Nov. 30, 2015 Baxalta Incorporated ... leader dedicated to delivering transformative therapies to ... conditions, today announced the launch and first ... an extended circulating half-life recombinant factor VIII ... full-length ADVATE [Antihemophilic Factor (Recombinant)]. The treatment ...
(Date:11/30/2015)... 2015 (HK$,000)For the Six Months Ended 30 September 2015 2014RestatedChange%Turnover 545,575 ... 421,979 , 384,242 , 9.8 ... 34,719 , (18.3) Medical Insurance Administration Service Income ... 16.1 Medical Devices and Accessories Sales , 89,645 ... Medicines Sales , 2,822 , 2,917 ...
(Date:11/30/2015)... , November 30, 2015 --> ... report "Dental Lasers Market by Product (Soft Tissue, All Tissue, ... User (Hospitals, Clinics), and Geography - Global Forecast to 2020", ... by 2020, at a CAGR of 5.2% during the forecast ... market data Tables and 62 Figures spread through 167 P ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... ... states in the U.S. require dental technicians to be certified or obtain continuing ... NADL created the “What’s In Your Mouth?” campaign to inform dentists that the ...
(Date:11/30/2015)... Los Angeles, CA (PRWEB) , ... November 30, 2015 , ... ... such as grafts, strip harvesting and follicular unit extraction. These techniques and procedures have ... of helping patients suffering from hair loss. While Dr. Parsa Mohebi, M.D. has utilized ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... its annual fundraising campaign to raise funds for its research, education, support, and ... of the organization’s annual funding. , The Mesothelioma Applied Research Foundation, which also ...
(Date:11/30/2015)... ... , ... Cycling, running, and walking are regular Sunday activities for many South ... 28, 2016. , That’s when the 7th annual ANF Group Tour de Broward ... and families at Joe DiMaggio Children’s Hospital. , The community fundraiser, sponsored ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... athletic teams looking to maximize recovery through quality sleep. Tim DiFrancesco, training coach ... get a better night’s sleep. ChiliPad precisely regulates the surface temperature of each ...
Breaking Medicine News(10 mins):